← Leaderboards
Qing-Sheng Mi
Henry Ford Health System
$11,290,442
Attributed
$22,353,289
Total exposure
16
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.3M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,353,289 · 16
By mechanism
R01$18,919,354 · 8
R21$1,226,330 · 3
R56$747,500 · 2
R61$746,480 · 1
R33$380,000 · 1
UG3$333,625 · 1
Top collaborators
- Indra Adrianto10 shared
- Wilson Liao8 shared
- Christian Posch6 shared
- James Tilford Elder5 shared
- Dafna D Gladman5 shared
- Li Zhou5 shared
- Shari Messinger4 shared
- Alberto Pugliese4 shared
Most similar at Henry Ford Health System
Same institution · by research overlap
- Indra Adrianto$1,711,081
Others in their field
Top investigators on “Insight”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- James Dennis Neaton · Northwestern University$283,212,546
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$278,513,775
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$200,435,757
Research focus
InsightAutoimmune DiseasesSkinImmuneCellsProteinsPathway InteractionsInflammatoryGenesVariantUntranslated RnaProceduresSkin DisorderCohortReportingMouse ModelMediatingMicrornasGeneticGene ExpressionGenome Wide Association StudyGenetic VariantCell PhysiologyLink
Grant awards (47)
VPS72 controls Treg cell stability and adaptation to tumor microenvironment$1,843,396
R01 · FY2025 · CA · contact PI
Multi-racial genetic analysis of hidradenitis suppurativa$665,897
R01 · FY2025 · AR
Immune receptor degradation for immune evasion of head and neck cancer$642,488
R01 · FY2025 · DE
Whole genome sequencing analysis of hidradenitis suppurativa$614,933
R01 · FY2025 · AR · contact PI
Anti-CD38 isatuximab Immunotherapy in Hidradenitis Suppurativa: a randomized, double-blinded, placebo-controlled, seamless phase 2a/2b trial$333,625
UG3 · FY2025 · AR · contact PI
Identification of Specific Immune Responses in African American Female Patients with Hidradenitis Suppurativa$219,799
R01 · FY2025 · AR · contact PI
Multi-racial genetic analysis of hidradenitis suppurativa$721,918
R01 · FY2024 · AR
Whole genome sequencing analysis of hidradenitis suppurativa$718,693
R01 · FY2024 · AR · contact PI
VPS72 controls Treg cell stability and adaptation to tumor microenvironment$602,346
R01 · FY2024 · CA · contact PI
Using whole-exome sequencing to uncover key genetic variants related to Hidradenitis Suppurativa risk in African American and Hispanic population.$228,000
R01 · FY2024 · AR
Multi-racial genetic analysis of hidradenitis suppurativa$750,965
R01 · FY2023 · AR
VPS72 controls Treg cell stability and adaptation to tumor microenvironment$658,092
R01 · FY2023 · CA · contact PI
Genetic and Genomic Dissection of Psoriatic Arthritis$586,059
R01 · FY2023 · AR
Genetic risk of hidradenitis suppurativa in African Americans$167,200
R21 · FY2023 · AR · contact PI
Multi-racial genetic analysis of hidradenitis suppurativa$93,412
R01 · FY2023 · AR
Multi-racial genetic analysis of hidradenitis suppurativa$749,217
R01 · FY2022 · AR
Genetic and Genomic Dissection of Psoriatic Arthritis$595,821
R01 · FY2022 · AR
Decoding TGF-beta signaling pathways in skin langerhans cells$376,250
R56 · FY2022 · AI · contact PI
Genetic risk of hidradenitis suppurativa in African Americans$200,640
R21 · FY2022 · AR · contact PI
Genetic risk of hidradenitis suppurativa in African Americans$152,000
R21 · FY2022 · AR · contact PI
Elucidating Systemic Inflammation in Hidradenitis Suppurativa using Single Cell Omics and Machine Learning$78,651
R01 · FY2022 · AR
Multi-racial genetic analysis of hidradenitis suppurativa$807,573
R01 · FY2021 · AR
Genetic and Genomic Dissection of Psoriatic Arthritis$608,486
R01 · FY2021 · AR
Uncover the new subsets of epidermal Langerhans cells$380,000
R33 · FY2021 · AR · contact PI
Genetic and Genomic Dissection of Psoriatic Arthritis$638,643
R01 · FY2020 · AR
microRNAs and NKT cell development and function$376,250
R01 · FY2020 · AI · contact PI
Uncover the new subsets of epidermal Langerhans cells$370,230
R61 · FY2020 · AR · contact PI
Roles of HDAC3 in Epidermal Langerhans Cell Ontogeny and Function$331,100
R01 · FY2020 · AR · contact PI
Serum miRNA Biomarkers of Islet Autoimmunity$740,959
R01 · FY2019 · AI
Genetic and Genomic Dissection of Psoriatic Arthritis$678,336
R01 · FY2019 · AR
Uncover the new subsets of epidermal Langerhans cells$376,250
R61 · FY2019 · AR · contact PI
microRNAs and NKT cell development and function$376,250
R01 · FY2019 · AI · contact PI
Roles of HDAC3 in Epidermal Langerhans Cell Ontogeny and Function$331,100
R01 · FY2019 · AR · contact PI
Serum miRNA Biomarkers of Islet Autoimmunity$746,950
R01 · FY2018 · AI
microRNAs and NKT cell development and function$376,250
R01 · FY2018 · AI · contact PI
Roles of HDAC3 in Epidermal Langerhans Cell Ontogeny and Function$331,100
R01 · FY2018 · AR · contact PI
Serum miRNA Biomarkers of Islet Autoimmunity$751,867
R01 · FY2017 · AI
microRNAs and NKT cell development and function$374,167
R01 · FY2017 · AI · contact PI
Roles of HDAC3 in Epidermal Langerhans Cell Ontogeny and Function$328,900
R01 · FY2017 · AR · contact PI
Serum miRNA Biomarkers of Islet Autoimmunity$773,669
R01 · FY2016 · AI
Roles of HDAC3 in epidermal Langerhans cell ontogeny and function$328,900
R01 · FY2016 · AR · contact PI
microRNAs and NKT cell development and function$249,167
R01 · FY2016 · AI · contact PI
microRNAs and NKT cell development and function$371,250
R56 · FY2015 · AI · contact PI
microRNA as biomarkers for the response to immunotherapy in melanoma$179,712
R21 · FY2013 · CA · contact PI
microRNA as biomarkers for the response to immunotherapy in melanoma$159,319
R21 · FY2012 · CA · contact PI
miRNAs and epidermal langerhans cell development and function$160,651
R21 · FY2011 · AR · contact PI
miRNAs and epidermal langerhans cell development and function$206,808
R21 · FY2010 · AR · contact PI